PAION is a specialty pharmaceutical company that develops innovative products for sedation and anesthesia including commercialization.  

 

Learn more About PAION

Remimazolam

PAION's lead compound, Remimazolam, is an ultra-short-acting intravenous Benzodiazepine sedative and anesthetic that is currently in Phase III clinical development for procedural sedation. Remimazolam has been investigated in more than 1,000 patients worldwide. 

PAION's Remimazolam

First half year results 2016

Teleconference & webcast

10 August 2016

Replay

Presentation

news

08/10/2016

Presentation H1 2016

Presentation H1 2016

Read more
08/10/2016

PAION AG reports financial results for the first half-year of 2016

PAION AG reports financial results for the first half-year of...

Read more
08/10/2016

Consolidated Financial Interim Report for the First Half Year 2016

Consolidated Financial Interim Report for the First Half-Year...

Read more
06/29/2016

Press Release: PAION completes private placement in the amount of EUR 9.6...

PAION completes private placement in the amount of EUR 9.6...

Read more
06/19/2016

Press Release: PAION reports positive remimazolam headline data in pivotal U.S....

PAION reports positive remimazolam headline data in pivotal U.S....

Read more
04/11/2016

Press Release: PAION successfully completes patient recruitment in Phase III...

PAION successfully completes patient recruitment in Phase III...

Read more

PAION Chart